Idaho is currently home to 363 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boise, Meridian, Idaho Falls and Nampa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392
Recruiting
The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
08/12/2025
Locations: Research Site, Boise, Idaho
Conditions: Gastric Cancer, Gastroesophageal Junction Cancer
Register for Updates
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383
Recruiting
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Viking Clinical Site #2080, Meridian, Idaho
Conditions: Weight Loss
Register for Updates
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
NCT06002828
Recruiting
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer sur... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Saint Luke's Cancer Institute - Boise, Boise, Idaho
Conditions: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Register for Updates
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806
Recruiting
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell'... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Register for Updates
Mobile Health for Adherence in Breast Cancer Patients
NCT06112613
Recruiting
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Breast Carcinoma, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Register for Updates
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
NCT05018585
Recruiting
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous beta cell function and influence glycemic parameters in adolescent and adults recently diagnosed with T1D carrying the HLA DR3-DQ2 haplotype.
Gender:
ALL
Ages:
Between 12 years and 28 years
Trial Updated:
08/12/2025
Locations: Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho
Conditions: Type 1 Diabetes Mellitus
Register for Updates
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
NCT06203600
Recruiting
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Im... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Register for Updates
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
NCT05136196
Recruiting
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Melanoma, Unresectable Melanoma
Register for Updates
Patient Retrospective Outcomes (PRO)
NCT01550575
Recruiting
This study will evaluate de-identified (anonymous) data in subject medical charts to review the clinical outcomes of various treatment approaches in the treatment of chronic pain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Pain and Spine Specialists of Idaho, Idaho Falls, Idaho
Conditions: Chronic Pain
Register for Updates
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
NCT02071134
Recruiting
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: St. Luke Regional Medical Center, Boise, Idaho
Conditions: Parkinson's Disease
Register for Updates
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
NCT03664609
Recruiting
The primary objective of this study is to characterize real-world clinical outcomes of Deep Brain Stimulation (DBS) using retrospective review of de-identified patient records.
Gender:
ALL
Ages:
All
Trial Updated:
08/11/2025
Locations: St. Luke's Regional Medical Center, Boise, Idaho
Conditions: Parkinson Disease, Essential Tremor, Dystonia
Register for Updates
Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
NCT06827262
Recruiting
Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: North Idaho Day Surgery, LLC, Post Falls, Idaho
Conditions: Chronic Low-back Pain, Vertebrogenic Pain Syndrome
Register for Updates